Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis.
Fatema AlrashedRobert BattatIsraa AbdullahAline CharabatyMohammad ShehabPublished in: BMJ open gastroenterology (2021)
In patients with IBD, the risk of severe COVID-19 is higher among patients receiving corticosteroids. Corticosteroid use was associated with ICU admission but not mortality. The risk is also higher among patients receiving 5-ASAs. However, patient-level data were lacking and insufficient data existed for meta-regression analyses to adjust for confounding. Vedolizumab, tofacitinib, and immunomodulators alone or in combination with anti-TNF were not associated with severe disease. Anti-TNFs, and ustekinumab were associated with favourable outcomes.
Keyphrases
- coronavirus disease
- ulcerative colitis
- sars cov
- rheumatoid arthritis
- electronic health record
- big data
- early onset
- emergency department
- healthcare
- case report
- respiratory syndrome coronavirus
- metabolic syndrome
- cardiovascular disease
- machine learning
- mechanical ventilation
- adipose tissue
- type diabetes
- artificial intelligence
- deep learning
- coronary artery disease